EPIX
ESSA Pharma
EPIX
EPIX
Delisted
EPIX was delisted on the 8th of October, 2025.
37 hedge funds and large institutions have $98.3M invested in ESSA Pharma in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
37
Holders Change
-8
Holders Change %
-17.78%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
11
Reduced
8
Closed
13
Calls
$549K
Puts
$477K
Net Calls
+$72K
Net Calls Change
+$179K
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$3.26M |
| 2 |
O
OrbiMed
New York
|
+$2.47M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$942K |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$819K |
| 5 |
Millennium Management
New York
|
+$727K |
Top Sellers
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$4.68M |
| 2 |
ABG
Ally Bridge Group
New York
|
-$1.71M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$1.52M |
| 4 |
D.E. Shaw & Co
New York
|
-$232K |
| 5 |
Two Sigma Investments
New York
|
-$125K |
